Drugs / Bovhyaluronidase azoximer
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06383819 | Apr 2022 → Dec 2023 | long COVID-19, polymyositis, pulmonary fibrosis | NPO Petrovax | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06458543 | Jun 2024 → Jun 2025 | bacterial vaginosis | I.M. Sechenov First Moscow State Medical University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06568718 | Mar 2023 → Feb 2024 | benign prostatic hyperplasia | NPO Petrovax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bovhyaluronidase azoximer | “Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID19: a multicenter, randomized, double-blind, placebo-controlled study.” PMID 42261259 ↗ Jun 2026 |
| Known as | Longidaza | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06458543 ↗ |
| Route | Intramuscular | “dose 3000 IU intramuscularly once every 5 days, 15 injections” NCT06383819 ↗ |